Table 1.
Patient and tumour characteristics at initial diagnosis in the germline variant study (n = 549).
| Factor | Group | All patients | Pathogenic germline BRCA1/2, PALB2 or ATM variants | |
|---|---|---|---|---|
| Yes | No | |||
| n = 549 | n = 29 | n = 520 | ||
| Age (median [IQR]) (year old) | 69.7 [64.0, 75.5] | 67.1 [58.5, 72.0] | 69.9 [64.1, 75.6] | |
| Initial PSA (median [IQR]) (ng/mL) | 111 [29.8, 469.3] | 255.5 [60.1, 867.0] | 108.5 [29.1, 432.8] | |
| Albumin (median [IQR]) (g/dL) at diagnosis | 4.2 [3.9, 4.4] | 4.0 [3.9, 4.3] | 4.2 [3.9, 4.4] | |
| LDH (median [IQR]) (U/L) at diagnosis | 192 [169, 237] | 212 [172, 251] | 191 [169, 237] | |
| Family history of cancer | ||||
| Prostate cancer (%) | No | 382 (96.0) | 14 (82.4) | 368 (96.6) |
| Yes | 16 (4.0) | 3 (17.6) | 13 (3.4) | |
| NA | 151 | 12 | 139 | |
| Breast cancer (%) | No | 386 (97.0) | 15 (88.2) | 371 (97.4) |
| Yes | 12 (3.0) | 2 (11.8) | 10 (2.6) | |
| NA | 151 | 12 | 139 | |
| Ovarian cancer (%) | No | 396 (99.5) | 17 (100.0) | 379 (99.5) |
| Yes | 2 (0.5) | 0 (0.0) | 2 (0.5) | |
| NA | 151 | 12 | 139 | |
| Pancreatic cancer (%) | No | 387 (97.2) | 15 (88.2) | 372 (97.6) |
| Yes | 11 (2.8) | 2 (11.8) | 9 (2.4) | |
| NA | 151 | 12 | 139 | |
| Any of the above (%) | No | 360 (90.1) | 11 (64.7) | 349 (91.6) |
| Yes | 38 (9.5) | 6 (35.3) | 32 (8.4) | |
| NA | 151 | 12 | 139 | |
| Past history of cancer | ||||
| Breast cancer (%) | No | 485 (99.8) | 25 (100.0) | 460 (100.0) |
| Yes | 1 (0.2) | 0 (0.0) | 1 (0.2) | |
| NA | 63 | 4 | 59 | |
| Colon cancer (%) | No | 467 (96.1) | 24 (96.0) | 443 (96.1) |
| Yes | 19 (3.9) | 1 (4.0) | 18 (3.9) | |
| NA | 63 | 4 | 59 | |
| Pancreatic cancer (%) | No | 482 (99.2) | 25 (100.0) | 457 (99.1) |
| Yes | 4 (0.8) | 0 (0.0) | 4 (0.9) | |
| NA | 63 | 4 | 59 | |
| Any of the above (%) | No | 463 (95.3) | 24 (96.0) | 439 (95.2) |
| Yes | 23 (4.7) | 1 (4.0) | 22 (4.8) | |
| NA | 63 | 4 | 59 | |
| Biopsy Grade group (%) | 1 | 8 (1.8) | 0 (0.0) | 8 (1.9) |
| 2 | 23 (5.1) | 0 (0.0) | 23 (5.3) | |
| 3 | 33 (7.3) | 1 (4.3) | 32 (7.4) | |
| 4 | 133 (293) | 8 (34.8) | 125 (29.0) | |
| 5 | 257 (56.7) | 14 (60.9) | 243 (56.3) | |
| NA | 95 | 6 | 89 | |
| Jewett stage (%) | A | 4 (0.7) | 0 (0.0) | 4 (0.8) |
| B | 38 (7.0) | 1 (3.4) | 37 (7.2) | |
| C | 56 (10.3) | 1 (3.4) | 55 (10.7) | |
| D1 | 39 (7.2) | 4 (13.8) | 35 (6.8) | |
| D2 | 406 (74.8) | 23 (79.3) | 383 (74.5) | |
| NA | 6 | 0 | 6 | |
| *CHAARTED volume (%) | Low | 153 (43.6) | 9 (39.1) | 144 (43.9) |
| High | 198 (56.4) | 14 (60.9) | 184 (56.1) | |
| NA | 100 | 4 | 96 | |
| Bone metastasis (%) | No | 165 (34.6) | 7 (28.0) | 158 (34.6) |
| Yes | 317 (65.8) | 18 (72.0) | 299 (65.4) | |
| NA | 67 | 4 | 63 | |
| Extent of disease (EOD) (%) | 0 | 165 (36.8) | 7 (29.2) | 158 (37.2) |
| 1 | 117 (26.1) | 5 (20.8) | 112 (26.4) | |
| 2 | 83 (18.5) | 6 (25.0) | 77 (18.1) | |
| 3 | 59 (13.1) | 4 (16.7) | 55 (12.9) | |
| 4 | 25 (5.6) | 2 (8.3) | 23 (5.4) | |
| NA | 100 | 5 | 95 | |
| Lung metastasis (%) | No | 439 (91.7) | 23 (92.0) | 416 (91.6) |
| Yes | 40 (8.4) | 2 (8.0) | 38 (8.4) | |
| NA | 70 | 4 | 66 | |
| Liver metastasis (%) | No | 471 (98.3) | 25 (100.0) | 446 (98.2) |
| Yes | 8 (1.7) | 0 (0.0) | 8 (1.8) | |
| NA | 70 | 4 | 66 | |
PS performance status by Common Toxicity Criteria, Version 2.0; Grade group by ISUP 2014, NA not available.
*CHAARTED volume was assigned only in the metastatic cases.